Everest Medicines (HKSE:01952) Change In Receivables : HK$-337.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Change In Receivables?

Everest Medicines's change in receivables for the quarter that ended in Dec. 2024 was HK$-111.5 Mil. It means Everest Medicines's Accounts Receivable increased by HK$111.5 Mil from Jun. 2024 to Dec. 2024 .

Everest Medicines's change in receivables for the fiscal year that ended in Dec. 2024 was HK$-335.2 Mil. It means Everest Medicines's Accounts Receivable increased by HK$335.2 Mil from Dec. 2023 to Dec. 2024 .

Everest Medicines's Accounts Receivable for the quarter that ended in Dec. 2024 was HK$388.2 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Everest Medicines's Days Sales Outstanding for the six months ended in Dec. 2024 was 163.77.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Everest Medicines's liquidation value for the six months ended in Dec. 2024 was HK$1,064.4 Mil.

Everest Medicines Change In Receivables Historical Data

The historical data trend for Everest Medicines's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Change In Receivables Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

22.07

-0.06

-5.77

-48.83

-335.18

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial							-4.44	4.80	-53.63	-225.54	-111.50

Everest Medicines Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-337.0 Mil.

Everest Medicines (HKSE:01952) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Everest Medicines's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	388.176	/	432.579	*	91
=	163.77

2. In Ben Graham's calculation of liquidation value, Everest Medicines's accounts receivable are only considered to be worth 75% of book value:

Everest Medicines's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1711.807	-	946.015	+	0.75 * 388.176	+	0.5 * 15.035
=	1,064.4

Everest Medicines Change In Receivables Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Gp Iv, L.p.	2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Iv, L.p.	2201 Interest of corporation controlled by you
Tf Capital Iv Ltd.	2201 Interest of corporation controlled by you
C-bridge Capital Gp, Ltd.	2501 Other
C-bridge Healthcare Fund Gp Ii, L.p.	2501 Other
C-bridge Healthcare Fund Ii, L.p.	2501 Other
C-bridge Investment Everest Limited	2501 Other
Tf Capital Ii Ltd.	2501 Other
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Fu Wei	2307 Founder of a discretionary trust who can infl
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse

Everest Medicines Headlines

No Headlines